Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel

Abstract

Aim: The primary objective of this review is to develop a practice-based expert group opinion on the role of precision medicine with a specific focus on sulfonylureas (SUs) in diabetes management.

Transform diabetes care with precision medicine

“…While personalized medicine primarily revolves around individual patient care within the patient-provider relationship, precision medicine forms an intricate ecosystem that interconnects patients with a broader network encompassing healthcare providers, researchers, and clinical laboratories. 21 The complexity of precision medicine notwithstanding, it has emerged as a pivotal paradigm in the field of medicine, particularly in enhancing the diagnosis, treatment, and management of chronic diseases like diabetes. Indeed, the integration of omics profiling technologies, big data, and machine learning in precision medicine for diabetes has the potential to revolutionize diabetes care.…”

“…In contrast, precision medicine extends beyond genomics, anchoring itself in data analytics and information‐driven healthcare models. While personalized medicine primarily revolves around individual patient care within the patient–provider relationship, precision medicine forms an intricate ecosystem that interconnects patients with a broader network encompassing healthcare providers, researchers, and clinical laboratories 21 . The complexity of precision medicine notwithstanding, it has emerged as a pivotal paradigm in the field of medicine, particularly in enhancing the diagnosis, treatment, and management of chronic diseases like diabetes.…”

“…To further improve precision medicine, it is important to invest in the best equipment and cultivate a thorough understanding of disease pathobiology 20 . In 2018, the Precision Medicine in Diabetes Initiative (PMDI) was launched by the American Diabetes Association and the European Association for the Study of Diabetes (EASD), with the aim of advancing precision diabetes care 21 …”

Precision Medicine of Autoimmune Diseases

“…The type 1 diabetes (T1D) takes place as a result of autoimmune beta-cell destruction, which leads to insufficient production of insulin and results in hyperglycemia [50]. Although the role of precision medicine in type 1 diabetes is not well defined, patient with T1D severity varies with difference in their pancreatic autoantibodies profile and the rate at which their beta cells destroy [51].…”

Factors Associated with Prolonged Poor Glycemic Control in Type 2 Diabetes Mellitus (T2DM) Patients Followed in the Department of Internal Medicine at the Yalgado Ouedraogo Teaching Hospital, Ouagadougou (Burkina Faso)

“…For them, each type of diabetes mellitus has its own specific characteristics due to epidemiology, environment, heredity, mode of onset, and progression [24] [ 25]. In addition, the criteria for defining poor glycemic control in the present effort is a methodological difference from the previous study.…”